Cell Therapy Manufacturing Market (By Therapy Type: Allogenic Cell Therapy, Autologous Cell Therapy; By Technology Type: Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, 3D Technology; By Source: IPSC, Bone Marrow, Umbilical Cord, Adipose Tissues, Neural Stem; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Therapy Manufacturing Market 

5.1. COVID-19 Landscape: Cell Therapy Manufacturing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell Therapy Manufacturing Market, By Therapy Type

8.1. Cell Therapy Manufacturing Market, by Therapy Type, 2024-2033

8.1.1. Allogenic Cell Therapy

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Autologous Cell Therapy

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Cell Therapy Manufacturing Market, By Technology Type

9.1. Cell Therapy Manufacturing Market, by Technology Type, 2024-2033

9.1.1. Somatic Cell Technology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Cell Immortalization Technology

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Viral Vector Technology

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Genome Editing Technology

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Cell Plasticity Technology

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. 3D Technology

9.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Cell Therapy Manufacturing Market, By Source 

10.1. Cell Therapy Manufacturing Market, by Source, 2024-2033

10.1.1. IPSC (Induced Pluripotent Stem Cell)

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Bone Marrow

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Umbilical Cord

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Adipose Tissues

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Neural Stem

10.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Cell Therapy Manufacturing Market, By Application 

11.1. Cell Therapy Manufacturing Market, by Application, 2024-2033

11.1.1. Musculoskeletal

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Gastrointestinal

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Neurological

11.1.4.1. Market Revenue and Forecast (2021-2033)

11.1.5. Oncology

11.1.5.1. Market Revenue and Forecast (2021-2033)

11.1.6. Dermatology

11.1.6.1. Market Revenue and Forecast (2021-2033)

11.1.7. Others

11.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Cell Therapy Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.1.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.3. Market Revenue and Forecast, by Source (2021-2033)

12.1.4. Market Revenue and Forecast, by Application (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.1.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Source (2021-2033)

12.1.6.4. Market Revenue and Forecast, by Application (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.2.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.3. Market Revenue and Forecast, by Source (2021-2033)

12.2.4. Market Revenue and Forecast, by Application (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.2.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Source (2021-2033)

12.2.6.4. Market Revenue and Forecast, by Application (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Source (2021-2033)

12.2.7.4. Market Revenue and Forecast, by Application (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Source (2021-2033)

12.2.8.4. Market Revenue and Forecast, by Application (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.3.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.3. Market Revenue and Forecast, by Source (2021-2033)

12.3.4. Market Revenue and Forecast, by Application (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.3.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Source (2021-2033)

12.3.6.4. Market Revenue and Forecast, by Application (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Source (2021-2033)

12.3.7.4. Market Revenue and Forecast, by Application (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Source (2021-2033)

12.3.8.4. Market Revenue and Forecast, by Application (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.3. Market Revenue and Forecast, by Source (2021-2033)

12.4.4. Market Revenue and Forecast, by Application (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.4.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Source (2021-2033)

12.4.6.4. Market Revenue and Forecast, by Application (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Source (2021-2033)

12.4.7.4. Market Revenue and Forecast, by Application (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Source (2021-2033)

12.4.8.4. Market Revenue and Forecast, by Application (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Source (2021-2033)

12.5.5.4. Market Revenue and Forecast, by Application (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Source (2021-2033)

12.5.6.4. Market Revenue and Forecast, by Application (2021-2033)

Chapter 13. Company Profiles

13.1. Abbott

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Catalent, Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bio-Techne

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Cytiva

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lonza

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. The Discovery Labs

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Bristol-Myers Squibb Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Gilead Sciences, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample